reaction products of 1,4-butanediol with 1,3-chloro-2,3-epoxypropane, esters with prop-2-enoic acid

Endpoint summary

Description of key information

No experimental toxicokinetic study is available on 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate.

However, as per REACH guidance document R7.C , information on absorption, distribution, metabolism and excretion may be deduced from the physical-chemical properties and QSAR predictions.

Based on the physical-chemical properties and QSAR predictions, the absorption of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is expected to be high by oral route and inhalation, low by dermal route. A good distribution and excretion of the substance are expected.

Key value for chemical safety assessment

Bioaccumulation potential:

no bioaccumulation potential

Absorption rate - oral (%):

100

Absorption rate - dermal (%):

10

Absorption rate - inhalation (%):

100

Additional information

No experimental toxicokinetic study is available on 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate. However, as per REACH guidance document R7.C, information on absorption, distribution, metabolism and excretion may be deduced from the physical-chemical properties, including:

-Mean molecular weight: 218 g/mol

-Water solubility: 86 mg/L

-Partition coefficient Log Kow: 2.5

-Vapour pressure: 0.000288 Pa (25°C)

 

ABSORPTION

Oral absorption: The moderate values of log Kow (2-4), the moderate solubility and the moderate molecular weight (below 500 g/mol) of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate are favorable for an oral absorption. The oral absorption is confirmed in the acute toxicity study, in which severe clinical signs and mortality were observed at 2000 mg/kg bw. The worst case value (100%) is used as oral absorption for the risk assessment.

Dermal absorption: With a high solubility of 86 g/L and a moderate log Kow, dermal absorption is anticipated to be moderate to high. According to the IH skin perm (QSAR), the dermal absorption of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is very low (<10 %). The substance showed allergic reaction in the LLNA: it is evidence that some uptake must have occurred although it may only have been a small fraction of the applied dose. For the risk assessment, 10% of dermal absorption is taken into account.

Inhalation absorption: Based on the low value of the vapour pressure (< 0.001 Pa), 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is considered as a low volatile substance.For the risk assessment, 100% of inhalation absorption is taken into account.

 

DISTRIBUTION and METABOLISM

No specific data is available on the distribution or metabolism of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate.

 

ELIMINATION

Due to the moderate molecular weight (< 300), the moderate water solubility and the moderate log kow, the excretion of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate in the urines is expected.